At 21x P/E, is Lupin an undervalued pharma giant poised for the next growth cycle?
Lupin stocks have been range-bound throughout 2025 after two years of a strong rally. Record earnings and USFDA approvals couldn’t move the stock much. Has the cyclical upside ended? Where is Lupin looking for new growth?
Lupin stocks have been range-bound throughout 2025 after two years of a strong rally. Record earnings and USFDA approvals couldn’t move the stock much. Has the cyclical upside ended? Where is Lupin looking for new growth?
What's Your Reaction?
:max_bytes(150000):strip_icc()/GettyImages-2187410260-5afe56694791404f99c253dd8d5abe6a.jpg?#)
